{{Rsnum
|rsid=4918758
|Gene=CYP2C9
|Chromosome=10
|position=96697252
|Orientation=plus
|GMAF=0.3526
|Gene_s=CYP2C9
|Assembly=GRCh37.p10
|GenomeBuild=37.5
|dbSNPBuild=138
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 12.4 | 46.9 | 40.7
| HCB | 14.6 | 53.3 | 32.1
| JPT | 22.1 | 45.1 | 32.7
| YRI | 8.8 | 38.8 | 52.4
| ASW | 8.8 | 38.6 | 52.6
| CHB | 14.6 | 53.3 | 32.1
| CHD | 13.8 | 42.2 | 44.0
| GIH | 27.7 | 40.6 | 31.7
| LWK | 10.9 | 47.3 | 41.8
| MEX | 6.9 | 43.1 | 50.0
| MKK | 9.6 | 44.2 | 46.2
| TSI | 14.7 | 36.3 | 49.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=24357089
|Title=Genetic Polymorphisms of Metabolic Enzymes and the Pharmacokinetics of Indapamide in Taiwanese Subjects
}}

{{PMID Auto
|PMID=18310303
|Title=Novel CYP2C9 promoter variants and assessment of their impact on gene expression.
|OA=1
}}

{{PMID Auto
|PMID=19761371
|Title=Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
|OA=1
}}

{{PMID Auto
|PMID=23469989
|Title=Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}